BfArM - Federal Institute for Drugs and Medical Devices

Navigation and service

International Networking

The DRKS meets the requirements of the ICMJE

The DRKS is the approved WHO Primary Register in Germany and thus meets the requirements of the International Committee of Medical Journal Editors (ICMJE). This committee which is a union of the publishers of the leading international medical journals (amongst others The Lancet, JAMA, NEJM) demands the prospective registration of clinical trials as requirement for any publication (recommendations). Numerous further medical journals support this call.

List of journals

The DRKS in the WHO network

The DRKS was designed in close collaboration with the WHO. The WHO brings together the worldwide activities for the registration of clinical trials on the International Clinical Trials Registry Platform (ICTRP). Its purpose is to allow exchange and to link and develop trial registers worldwide. That means e.g. standardisation of processes to get harmonised data collection and ensure consistent data quality. As a Primary Register, the DRKS is a member of the ICTRP network.

A flyer on the ICTRP can be found here.

Global search for clinical trials

In order to enable a global search for clinical trials the WHO started the ICTRP meta register in May 2007 in which all registers involved bring their data together. A list of the involved registers can be found on the WHO Website.

Primary Registry: requirements

Clinical trial registries must, among other conditions, collect at least the minimum WHO data set of 24 parameters and submit them in English to the WHO portal in order to become an approved primary registry of the WHO. In order to exclude any influence on the registration and data collection, primary registries should also be managed by an independent organization or institution. Primary registries have to be publicly accessible free of charge and have a national mandate. On the one hand, WHO wants to ensure that only one registry from each country provides pooled data to the WHO portal. On the other hand, it demands national legitimacy and support for the study registries. For Germany, the DRKS fulfills all requirements and was therefore recognized by the WHO as a primary registry in October 2008.

Cooperation with Ethics Committees

Background: Trial registration is an ethical responsibility

The World Medical Association states in the Declaration of Helsinki, which is a set of ethical principles accepted as a guideline for clinical research worldwide, in paragraph 35:

"Every research study involving human subjects must be registered in a publicly accessible database before recruitment of the first subject."

The WHO states on its website:

The registration of all interventional trials is a scientific, ethical and moral responsibility.

Why?

Clinical research has to meet the highest ethical principles.

People participate in clinical trials not only to profit of innovative therapies but also by the conviction to support medical progress with their participation and thus help future patients with the newly won knowledge.

Therefore, it is not just a scientific but also an ethical necessity to make the results of all clinical trials accessible immediately and in an undistorted way (usually as a scientific publication in a journal). However, according to observation in several countries only about 50 % of the once started trials are in the end published.

Publicly accessible study registries counteract this deficiency. With the help of the DRKS and other study registries, a public birth certificate of each study is created as a first step towards ensuring the complete visibility of all study results. This will make subsequent "disappearance" impossible and allow results to be searched even if there are no publications in a journal.

At the end of 2022, the "Study Results" section in DRKS was completely revised and now makes the publication of study results even easier.

Cooperation with Medical Ethics Committees in Germany

The necessity of a trial registry from the point of view of an ethics committee was pointed out in 2004 by Victor in "Deutsches Ärzteblatt". Ethics committees assess the risk-benefit ratio for individual participants and the significance of the research project for medical advancement. Furthermore, they assure that patients are adequately informed. The basis for this is knowledge on all finished and ongoing clinical trials as well as the available evidence related to the issue at hand. Because many clinical trials are not published immediately or are not published at all, comprehensive trial registries are necessary to facilitate a meta-analysis before the beginning of each trial. This is the only way to ensure that intended projects are put into perspective to the existing evidence, redundant studies are avoided, and findings are put into practice sooner.

Support through the Workgroup of Medical Ethics Committees

The workgroup of Medical Ethics Committees already stand up for the foundation of a clinical trial registry in 2003. In March 2013 the workgroup spoke in favour for the need of a registration obligation and for the implementation of this demand by statute. The president of the board of the German Medical Ethics Committee workgroup supports the German Clinical Trials Register through its membership in the scientific advisory board.

The workgroup of Medical Ethics Committees in Germany is supporting the German Clinical Trials Registry since its foundation in 2008.

Use of cookies

Cookies help us to provide our services. By using our website you agree that we can use cookies. Read more about our Privacy Policy and visit the following link: Privacy Policy (only in German)

OK